Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy.
Heifets
L B
LB
National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D066298:In Vitro Techniques; D015269:Mycobacterium avium Complex / Q000187:drug effects* / Q000302:isolation & purification; D015270:Mycobacterium avium-intracellulare Infection / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D017828:Rifabutin / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D017828:Rifabutin; D017291:Clarithromycin